期刊文献+

神经元特异性烯醇化酶、癌胚抗原、乳酸脱氢酶在小细胞肺癌中的预后价值比较 被引量:10

Comparative Prognostic Value of Neuron-specific Enolase Carcinoembryonic Antigen and Lactate Dehydrogenase in Small-cell Lung Cancer Patients
下载PDF
导出
摘要 目的 评价神经元特异性烯醇化酶(NSE)、癌胚抗原(CEA)、乳酸脱氢酶(LDH)在小细胞肺癌(SCLC)患者中的预后价值。方法 收集苏州大学附属第二医院1997年12月至2 0 0 3年11月确诊的4 6例非手术治疗的SCLC患者,在治疗前检测NSE、CEA、LDH及其它实验室指标,进行预后单因素和多因素分析。结果 NSE、CEA、LDH的升高率分别为4 8.3%、4 2 .9%、30 .4 % ,三者水平在广泛期均高于局限期,其中LDH、CEA有显著统计学意义(P <0 .0 5 )。单因素分析NSE >12ng/ml,、LDH >1(与上限比值)均是提示预后较差的指标。多因素分析时,NSE是独立的预后因子,LDH、CEA的影响不明显。结论 NSE、CEA、LDH中,NSE与预后的相关性最强,是提示预后的独立指标。 Objective To evaluate the prognostic significance of neuron-specific enolase(NSE)carcinoembryonic antigen(CEA)lactate dehydrogenase(LDH) in small-cell lung cancer(SCLC). Methods A total of 46 histologically proven and unresectable SCLC patients were included. NSECEALDH and other laboratory variables were tested before therapy. Results LDH was elevated in 30.4% of the patients,CEA in 42.9%,NSE in 48.3%.Among them LDH and CEA were significantly higher when the disease was considered extensive than when it was limited.The univariate analysis showed that patients whose NSE is greater than 12 ng/ml,LDH is greater than 1(ratio of this value to the upper limit) had a significant shorter survival in comparison with the opposite status of each variables.The multivariate survival analysis showed that NSE was a more important prognostic factor than LDH and CEA. Conclusion NSE is an independent prognostic factor for small-cell lung cancer.
出处 《苏州大学学报(医学版)》 CAS 北大核心 2005年第2期261-264,共4页 Suzhou University Journal of Medical Science
关键词 神经元特异性烯醇化酶 癌胚抗原 乳酸脱氢酶 小细胞肺癌 预后 NSE CEA LDH small-cell lung cancer prognostic factor
  • 相关文献

参考文献7

  • 1Chute JP,Chen T,Feigal E,et al.Twenty years of phase Ⅲ trials for patients with extensive stage small-cell lung cancer:perceptible progress[J].J Clin Oncol,1999,17:1794-801.
  • 2Quoix E,Purohit A,Faller-Beau M,et al.Comparative prognostic value of lactate dehydrogenase and neuron-specific enolase in small-cell lung cancer patients treated with platinum-based chemothetapy[J]. Lung Cancer,2000,30:127-134.
  • 3Pujol JL,Daures JP,Rivere A,et al.Etoposide plus isplatin with or without the combination of 4'-epidoxorubicin and cyclophosphamide in the treatment of extensive stage small cell lung cancer.A FNCLCC multicentre phase randomized study[J].J Natl Cancer Inst, 2001,93:300-308.
  • 4Janne PA,Freidlin B,Saxman S,et al.The survival of patients treated for limited stage small cell lung cancer in North America has increased during the past 20 years[J].Proc Am Cancer Soc,2001,20:A1264.
  • 5Shibayama T,Ueoka H,Nishii K,et al.Complementary roles of pro-gastrin-releasing peptide(ProGRP) and neuron specific enolase(NSE) in diagnosis and prognosis of small-cell lung cancer(SCLC)[J].Lung Cancer,2001,32:61-9.
  • 6Pujol JL,Quantin X,Jacot W,et al.Neuroendocrine and cytokeratin serum markers as prognostic determinants of small cell lung cancer[J].Lung Cancer,2003,39:131-138.
  • 7Bonner JA,Sloon JA,Rowland KMJ,et al.Significance of neuron-specific enolase levels before and during therapy for small cell lung cancer[J].Clin Cancer Res,2000,6:597-601.

同被引文献112

引证文献10

二级引证文献72

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部